Comparative Pharmacology
Head-to-head clinical analysis: PFIZERPEN AS versus PFIZERPEN G.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PFIZERPEN AS versus PFIZERPEN G.
PFIZERPEN-AS vs PFIZERPEN G
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PFIZERPEN-AS (penicillin G procaine) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and transglycosylation, leading to cell lysis.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin inhibition.
250-500 mg orally every 6-8 hours for moderate infections; 500 mg to 2 g intravenously every 4-6 hours for severe infections.
2-4 million units (1.2-2.4 g) IV every 4-6 hours; maximum 24 million units per day.
None Documented
None Documented
0.5-1 hour in healthy adults; prolonged to 2.5-10 hours in renal impairment (CrCl <10 mL/min). Clinically relevant for dosing interval adjustment in renal dysfunction.
Terminal elimination half-life is 30-60 minutes in patients with normal renal function; prolonged to 2-10 hours in renal impairment (CrCl <10 mL/min).
Primarily renal (60-80% as unchanged drug via tubular secretion and glomerular filtration); minor biliary/fecal elimination (10-20%)
Primarily renal excretion via glomerular filtration and tubular secretion; 60-90% of dose excreted unchanged in urine within 6 hours. Biliary excretion accounts for less than 10%.
Category C
Category C
Antibiotic (Penicillin)
Antibiotic (Penicillin)